SLDB Expense Breakdown
Solid Biosciences Inc. (SLDB). Quarter ended 2020-09-30 · each product line is listed as filed.
- 2026-06-30: S G T 003 $24.52M; Internal Research and Development Expense $9.06M; Sgt-212 $2.36M; S G T 501 $903.00K.
- 2025-06-30: S G T 003 $12.22M; Internal Research and Development Expense $6.76M; Sgt-212 $1.15M; S G T 501 $2.22M.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | S G T 003 | Internal Research and Development Expense | Sgt-212 | S G T 501 |
|---|---|---|---|---|
| 2026-06-30 | $24.52M | $9.06M | $2.36M | $903.00K |
| 2025-06-30 | $12.22M | $6.76M | $1.15M | $2.22M |
General and Administrative Expense: each quarter (3 month)
| Quarter end | External General and Administrative Expense | Internal General and Administrative Expense |
|---|---|---|
| 2026-06-30 | $6.33M | $4.73M |
| 2025-06-30 | $5.28M | $3.36M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |